Clinical Trials | June 01, 2026
Pfizer’s drug combo shows strong survival results in aggressive prostate cancer trial
This marks one of the most closely watched oncology readouts at this year’s medical congress
This marks one of the most closely watched oncology readouts at this year’s medical congress
Despite the strong results, investigators cautioned that the study has limitations, including its open-label Phase II design, lack of randomization, and reliance on a historical external control arm
Darolutamide Tablets, 300 mg, had an estimated market size of US$ 3,155 million in the United States
The trial met its primary endpoint, with the combination therapy demonstrating a “statistically significant and clinically meaningful” improvement in radiographic progression-free survival
The study hit its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) compared to placebo plus XTANDI
Patients with BRCA mutations often face aggressive disease and poor prognosis
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Study achieves primary endpoint of radiographic progression-free survival
Subscribe To Our Newsletter & Stay Updated
